BIOCRYST PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00061880
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
Phase 1
Completed
- Conditions
- Leukemia, LymphocyticLymphoma
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-01-13
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT00035022
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
A Study of Peldesine (BCX-34) in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00002237
- Locations
- 🇺🇸
Saint Francis Mem Hosp / HIV Care Unit, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath